Vijay  Tammara net worth and biography

Vijay Tammara Biography and Net Worth

SVP of Ocugen
Dr. Tammara has over 20 years of leadership experience in global regulatory affairs, strategic drug development, and clinical strategy, contributing significantly to the approval of several products. His regulatory expertise spans both oral and injectable dosage forms of small molecules, peptides, proteins, monoclonal antibodies and vaccines. Dr. Tammara served previously as Vice President of Regulatory Affairs at Nuron Biotech Inc., Director of Regulatory Affairs at Merck & Co., Inc., Senior Associate Director at Wyeth Pharmaceuticals, and Assistant Director at Sanofi-Synthelabo in Worldwide Regulatory Affairs. Prior to industrial positions, Dr. Tammara held positions of increasing responsibility in the Office of Clinical Pharmacology and Biopharmaceutics at the U.S. FDA, where he received several awards, including the CDER Outstanding Reviewer Award, FDA Outstanding Achievement Award, and Awards of Excellence. Dr. Tammara received his Bachelor of Pharmacy from Kakatiya University, Masters in Pharmacy from Nagpur University, and Ph.D. in Pharmaceutics from the University of Louisiana, Monroe.

What is Vijay Tammara's net worth?

The estimated net worth of Vijay Tammara is at least $14,310.00 as of May 3rd, 2021. Dr. Tammara owns 9,000 shares of Ocugen stock worth more than $14,310 as of April 16th. This net worth evaluation does not reflect any other investments that Dr. Tammara may own. Learn More about Vijay Tammara's net worth.

How do I contact Vijay Tammara?

The corporate mailing address for Dr. Tammara and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Vijay Tammara's contact information.

Has Vijay Tammara been buying or selling shares of Ocugen?

Vijay Tammara has not been actively trading shares of Ocugen during the last quarter. Most recently, Vijay Tammara sold 4,317 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $16.00, for a transaction totalling $69,072.00. Following the completion of the sale, the senior vice president now directly owns 9,000 shares of the company's stock, valued at $144,000. Learn More on Vijay Tammara's trading history.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Are insiders buying or selling shares of Ocugen?

In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.

Information on this page was last updated on 6/14/2023.

Vijay Tammara Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2021Sell4,317$16.00$69,072.009,000View SEC Filing Icon  
4/29/2021Sell29,991$10.97$329,001.279,000View SEC Filing Icon  
See Full Table

Vijay Tammara Buying and Selling Activity at Ocugen

This chart shows Vijay Tammara's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.59
Low: $1.52
High: $1.60

50 Day Range

MA: $1.16
Low: $0.52
High: $1.88

2 Week Range

Now: $1.59
Low: $0.35
High: $2.11

Volume

2,980,150 shs

Average Volume

8,161,378 shs

Market Capitalization

$407.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.51